Aim Assess the risk of zinc (Zn) deficiency in the older cystic fibrosis (CF) population. Method Cross-sectional investigation of all CF patients above the age of 4 followed at the Ghent University center between 2002 and 2003. Data on age, weight, height z-score, pancreatic and pulmonary functions, chronic Pseudomonas infection, and CF transmembrane conductance regulator (CFTR) mutations were collected. Serum Zn, vitamins (vit) A and E, retinol-binding protein (RBP), albumin, sedimentation rate, total IgG, and cholesterol were determined. Serum Zn was compared with a local healthy control group (Van Biervliet et al., Biol Trace Elem Res 94:33-40, 2003) and with literature data (Hotz C, et al. Am J Clin Nutr 78:756-764, 2003). Results 101 patients (median age 16 years) were included. There was no difference in serum Zn concentration between CF patients and controls. In CF patients no difference in serum Zn concentration between pancreatic-sufficient or pancreatic-insufficient patients was seen. Serum Zn was not associated to nutritional status or height z-score. A significant association serum Zn to serum albumin (p<0.0005) and to vit A (p<0.01) was seen. No associations of serum Zn to serum vit E, RBP, cholesterol, or CFTR were present, but there is a significant association serum Zn to forced vital capacity (p<0.01). Serum Zn was not associated to inflammatory parameters or chronic Pseudomonas infection. Conclusion Comparison of CF patients with local controls revealed no significant differences. However, because persisting steatorrhea increases Zn loss (Easley et al., J Pediatr Gastroenterol Nutr 26:136-139, 1998) and 12.6% of our population has a serum Zn below the p value of 2.5 of the NHANES II study (Hotz C, et al. Am J Clin Nutr 78:756-764, 2003), there could remain an increased risk of Zn deficiency in some CF patients. Furthermore, the association with pulmonary function needs more investigation.
Introduction
Assessment of marginal zinc (Zn) status in humans is problematic. The serum Zn is far from the ideal method because it lacks sensitivity and specificity to evaluate the Zn status. It is, however, a useful biomarker of a population's risk of Zn deficiency and can be used to determine whether interventions on the Zn status are needed [1] . Zinc deficiency was originally described in 1961 by Prasad et al. [2] . The symptoms of Zn deficiency are stunted growth, delayed sexual maturation, disturbed immunity, poor appetite, and diarrhea each of which are frequently present in patients with cystic fibrosis (CF) [3] [4] [5] .
In a previous contribution, newly diagnosed, untreated CF patients were compared to healthy age-matched controls and no differences of serum Zn concentrations were observed in CF as well as at diagnosis and after 1 year of CF therapy [6] . Because many of the older CF patients still present symptoms also commonly seen in Zn deficiency, a cross-sectional study of the serum Zn concentration of treated CF patients was performed here.
Subjects and Methods
This is a cross-sectional study of all CF patients over the age of 4 followed at a CF center in Ghent during the period of 2002-2003 (n=101, female=48) . From the age of 4 serum Zn is leveling in previously described normal controls [7] . Therefore, CF patients from the age of 4 are compared to 174 local controls and reference values [7, 8] .
All were treated during at least 1 year. None of the patients took Zn supplements. Pancreatic-insufficient (PI) patients (n=90) received pancreatic exocrine replacement therapy and fat soluble vitamin (vit) supplements targeted to the serum values.
In patients above the age of 6 (n=90) the pulmonary function was measured every 3 months on a Jaeger Masterscreen Body, a half year before and after the Zn determination. For evaluation of lung function the mean value of the five measurements was considered.
Laboratory Analysis
Blood was drawn by venepuncture after an overnight fasting of 8 h and collected in a Znfree tube. After clotting and centrifugation, the serum was stored at −60°C until examination.
Zinc was determined on a PerkinElmer 2380 flame atomic spectrophotometer, as described by Carter [9] , adapted according to Dubrowski [10] . Serum α-tocopherol and retinol were analyzed by isocratic high-pressure liquid chromatography [11] . Total cholesterol was measured using an enzymatic colorimetric analysis as described by Allain et al. [12] . Serum albumin was determined by the Bromcresol green method of COBAS 6000® (Roche Diagnostics). The serum retinol-binding protein (RBP) concentration was measured on a Behring Nephelometer Analyzer II.
Genotypes were determined with the INNO-LiPA CFTR19 ® and INNO-LiPA CFTR17+ Tn Update ® kit (Innogenetics N.V.) or sequencing of the CF transmembrane conductance regulator (CFTR) genome. CFTR gene mutations were classified as proposed by Welsh and Smith [13] using the CF mutation database http://www.genet.sickkids.on.ca). Group A included patients with type I, II, or III mutations resulting in no functional CFTR protein.
Group B included patients with at least one type IV or V mutation resulting in a partially functional CFTR protein or those with unknown effect on the CFTR protein (Table 1) . 
Statistics

Results
Patients
There were 101 patients (48 females) included. Their median age was 16 years (IQR 11.2). The median age for gender was not different. Eleven patients were pancreatic-sufficient (PS). The percentage of ideal weight for height (W/H %) was 98% (IQR 14.95). There was no significant difference in W/H % according to gender or pancreatic function. The height z-score (H z-score) was −1.3 (IQR 1.2). Girls were significantly more stunted than the boys with a median H z-score of −1.6 (IQR 1.3) vs −1.1 (IQR 1.03) (p<0.03). None of the patients was vegetarian. The median forced expiratory volume in 1 s (FEV1%) was 82.8% (IQR 39.1) and the forced vital capacity (FVC%) was 91.7% (IQR 27.25). There were 39 (IQR 38.5) patients colonized with Pseudomonas aeruginosa. They had a significantly worse pulmonary function (p<0.03). FVC% was 96.6% (IQR 25) for Pseudomonasnegative and 87.3% (IQR 27.2) for the colonized patients.
The CFTR mutation subgroups are described in Table 1 . Group A includes mutations where no CFTR function is expected (n=68). Group B includes mutations with decreased function or unknown effect on CFTR function (n=33). All PS patients were in group B.
There were no significant differences in the clinical parameters between the genotype groups except for the H z-score (p<0.02). Group B (H z-score −1.2, IQR 1.375) was significantly taller than group A (H z-score −1.4, IQR 1.43) (p<0.02). Group B had higher serum cholesterol (145 mg/dl, IQR 48.75) than group A (132 mg/dl, IQR 50) (p<0.02). The other laboratory data did not differ between the genotype groups.
Serum Zinc Concentration
The median serum Zn concentration was 82 μg/dl (IQR 20). There was no difference between the CF patients and the healthy local controls (84 μg/dl, IQR 24). However, the age range in the control group was significantly lower with a median age of 6.5 year (4-13.8 year). Considering a fully age-matched CF patients (n=42), similar results were obtained.
Of our CF population and healthy controls, 16.8 and 12.6%, respectively, had a serum Zn below the lower cut-off (2.5 percentile=65 μg/dl) of the NHANES II [8] . 
There was no difference according to gender or age. Dividing the CF patients in the age classes of NHANES II (<18, 18-25, and >25 years), no differences were found.
Serum Zn is not associated with nutritional status expressed as W/H % or H z-score. Even between patients with high or low (<65 μg/dl) serum Zn no differences in growth and nutritional status could be observed.
There was no statistical evidence of differences in serum Zn between PS (n=11) (82.9 μg/dl, IQR 21) and PI patients (n=90) (81.5 μg/dl, IQR 16.25). However, none of the PS CF patients had a serum Zn below 65 μg/dl.
Comparing serum Zn of the genotype classes, no differences were seen. However, in group A 17.6% (n=12) and in group B 15% (n=5) had serum Zn below the lower cut-off (P 2.5=65 μg/dl) of NHANES II [8] .
Serum Zinc and other Serum Values in Cystic Fibrosis Patients
A significant association between serum Zn and albumin (p<0.0005) and Zn-serum vit A (p<0.01) were obvious. There was no association of serum Zn with cholesterol, RBP, vit E, or with markers of inflammation (erythrocyte sedimentation rate, total IgG).
Serum Zinc and Pulmonary Function
There was no difference in serum Zn between patients with or without Pseudomonas colonization. The pulmonary function in colonized patients (FVC% 87.3%, IQR 27.3) was, however, significantly lower (p<0.004). There was no association between Zn and FEV1% but a significant association was found with FVC% (p<0.01) (Fig. 1) .
Discussion
Zinc has the second highest prevalence of all oligoelements in the human body [14] . One could distinguish three main categories of Zn functions: catalytic, structural, and regulatory. Zinc is an essential component of the catalytic site of hundreds of different metalloenzymes [15] . Furthermore, it is on an important structural element of gene regulatory proteins [16] . The structure of these proteins is dependent on Zn chelation centers. At these sites Zn Tied P< 0.01 spearman rank correlation Fig. 1 Correlation between serum Zn and FVC% facilitates appropriate protein folding. These "Zn finger" proteins play a key role in formation and maintenance of all tissues [17] . The last function of Zn is regulatory. It acts as an ionic signal in cells through gated membrane channels [18] . More than 300 enzyme systems rely on its presence [19, 20] .
Therefore, Zn deficiency symptoms are nonspecific. They include loss of appetite, diminished sense of taste, growth retardation, disturbed immune functions, impaired wound healing, and other skin changes [3] [4] [5] 21] . Patients with CF can have similar symptoms.
Serum Zn remains the easiest and most widely used index of Zn status for population research. For determination of an individual Zn status, serum Zn lacks optimal sensitivity and specificity [1] . Zinc is located in the cell and only a small portion is found in the circulation bound to plasma protein [14] . As about 70% of the plasma Zn is bound to albumin [14] , the correlation (p<0.0005) found between serum Zn and albumin is not surprising.
Multiple aspects of the vit A status (absorption, metabolism, release, transport, and utilization) may be influenced by Zn [22] . A significant association of Zn with vit A has been described in multiple other populations [23, 24] and is confirmed in this study despite the treatment with high doses of vit A. Zinc is required for hepatic synthesis of RBP, implying a regulatory role for Zn in mobilizing vit A within cells and from the liver [25] . As observed by others [26] , there was, however, no association of serum Zn and RBP in this CF population.
Although the influence of Zn on vit A absorption [22] opens interesting theories concerning the possibilities of improving the vit A status of CF patients by Zn supplementation, they were not confirmed in therapeutic trials [27] .
Acrodermatitis enteropathica-like eruption is regularly described as a presenting picture of CF [28] [29] [30] . Because in our healthy controls [7] 12.6% has a serum Zn concentration below the lower cut-off of the NHANES II study [8] , they could be considered as a population at risk for Zn deficiency. Therefore it is interesting to have a closer look at populations with diseases known to cause increased Zn losses such as CF [31, 32] , especially because the data on prevalence of Zn deficiency in the CF population are inconsistent [32] [33] [34] [35] [36] . This study confirms the absence of a difference in serum Zn between treated CF patients and controls [33, 35] . Because of the small study size, the age-related fluctuations described in NHANES II study are not consistent [8] .
In general the severity of malabsorption is less pronounced in PS CF patients. In this population it is reflected by their higher H z-score and serum cholesterol values. The group of Hambidge [31] showed a decreased fractional absorption of Zn in PI CF and its increase by pancreatic enzyme supplementation. The fecal Zn loss correlated with fecal fat loss [32] . From our CF population 16.8% had Zn values below the NHANES II cut-off. This was, however, exclusively seen in PI CF.
As observed by other groups [35, 37] , the absence of association Zn nutritional status in this study population is not surprising because malnutrition in CF is a complex multifactorial problem. It is influenced a.o. by nutritional intake, absorption, and energy expenditure.
The relation between serum Zn and pulmonary function merits further investigation. Inflammation is more frequently present in patients with decreased pulmonary function. Inflammatory conditions are known to reduce serum Zn concentrations [38] . There was, however, no association between serum Zn and red blood cell sedimentation rate or total IgG, which are both parameters of inflammation. Although patients colonized by P. aeruginosa had a significantly lower pulmonary function, there was no difference in serum Zn according to the colonization status. Because Zn plays an important role in immunity [21] the decreased serum Zn in patients with decreased pulmonary function could enhance infection, leading to a vicious circle. Zinc supplementation reduces pulmonary infections in many different conditions [39, 40] and it can be interesting to investigate such in CF, especially in those patients with low serum Zn values. The only double-blind Zn supplementation study in CF did not select the population according the initial serum Zn value. They were not able to observe differences in nutritional status or pulmonary function after the 8-week short duration of the Zn supplementation [27] . Probably the effects of Zn supplementation could be more pronounced in the initially low Zn group.
Conclusion
A subgroup of CF patients shows marginal serum Zn and could be at risk of its major metabolic consequences. In this condition Zn supplementation needs to be thoroughly examined. Furthermore, the decreased long function of the low Zn group needs more attention.
